Is there a generic for Sumatriptan succinate?

Yes. The FDA Orange Book lists 38 approved generic (ANDA) applications for Sumatriptan succinate, referencing the brand ZEMBRACE SYMTOUCH. Generics rated with an "A" therapeutic-equivalence code are considered substitutable for the brand.

What is the reference-listed drug for Sumatriptan succinate?

ZEMBRACE SYMTOUCH (NDA 208223, TONIX MEDS) is the reference-listed drug, the approved product a generic applicant must show its version is the same as.

What patents protect Sumatriptan succinate?

The Orange Book lists 27 patents against Sumatriptan succinate products, with the earliest listed expiry in 2026. Listed patents cover the drug substance, drug product, or approved methods of use, and a generic launching before they expire must file a Paragraph IV certification.

What dosage forms of Sumatriptan succinate are approved?

Sumatriptan succinate is approved in the following dosage forms: injectable, powder, solution, system, tablet.

FDA Orange Book · active-ingredient family

Sumatriptan succinate

Sumatriptan succinate: 7 brands, 38 generics; first approved Dec 28, 1992; generic available.

Generic availableHas discontinued products

Generic status & protection

Generic available: 38 ANDA applications approved.

Earliest patent expiry Feb 23, 2026

Brands (NDA)

Generics (ANDA)

Listed patents

Next patent expiry

Feb 23, 2026

6 mo ago

Brand (NDA) products

Originator applications

ZEMBRACE SYMTOUCHRLD
TONIX MEDSNDA 2082232016
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) SOLUTION SUBCUTANEOUS Rx —
ONZETRA XSAILRLDRS
CURRAXNDA 2060992016
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 11MG BASE POWDER NASAL Rx —

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	SOLUTION	SUBCUTANEOUS	Rx	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 11MG BASE	POWDER	NASAL	Rx	—

SUMAVEL DOSEPRORLD

ENDO OPERATIONSNDA 02223920132 strengths

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Discontinued	—
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Discontinued	—

ZECUITYRLD
TEVA BRANDED PHARMNDA 2022782013
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6.5MG BASE/4HR SYSTEM IONTOPHORESIS Discontinued —
IMITREXRLD
GLAXOSMITHKLINENDA 02013219953 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 100MG BASE TABLET ORAL Rx AB
EQ 25MG BASE TABLET ORAL Rx AB
EQ 50MG BASE TABLET ORAL Rx AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6.5MG BASE/4HR	SYSTEM	IONTOPHORESIS	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 100MG BASE	TABLET	ORAL	Rx	AB
EQ 25MG BASE	TABLET	ORAL	Rx	AB
EQ 50MG BASE	TABLET	ORAL	Rx	AB

IMITREXRLD

GLAXOSMITHKLINENDA 02008019923 strengths

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Discontinued	—
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AB
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AB

ALSUMA
MERIDIAN MEDCLNDA 0223772010
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Discontinued —

Generic (ANDA) products (38)

Abbreviated applications

SUMATRIPTAN SUCCINATE
ALEMBICANDA 21351820252 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) INJECTABLE SUBCUTANEOUS Rx AB
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Rx AB
SUMATRIPTAN SUCCINATE
IPCA LABS LTDANDA 20601920253 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Rx AB
EQ 50MG BASE TABLET ORAL Rx AB
EQ 100MG BASE TABLET ORAL Rx AB
SUMATRIPTAN SUCCINATE
VKT PHARMAANDA 21903620243 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Rx AB
EQ 50MG BASE TABLET ORAL Rx AB
EQ 100MG BASE TABLET ORAL Rx AB
SUMATRIPTAN SUCCINATE
ONESOURCE SPECIALTYANDA 2156512024
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Rx AP
SUMATRIPTAN SUCCINATE
BAXTER HLTHCARE CORPANDA 2071012023
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Discontinued —
SUMATRIPTAN SUCCINATE
CAPLINANDA 2139982021
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Rx AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AB
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Rx	AB
EQ 50MG BASE	TABLET	ORAL	Rx	AB
EQ 100MG BASE	TABLET	ORAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Rx	AB
EQ 50MG BASE	TABLET	ORAL	Rx	AB
EQ 100MG BASE	TABLET	ORAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AP

SUMATRIPTAN SUCCINATE

ANTARES PHARMA INCANDA 07831920152 strengths

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Discontinued	—
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Discontinued	—

SUMATRIPTAN SUCCINATE
NORVIUM BIOSCIENCEANDA 2033222014
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Discontinued —
SUMATRIPTAN SUCCINATE
DR REDDYSANDA 0904952014
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Rx AB
SUMATRIPTAN SUCCINATE
HIKMAANDA 2001832013
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Rx AP
SUMATRIPTAN SUCCINATE
HIKMA PHARMSANDA 07829820133 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Discontinued —
EQ 50MG BASE TABLET ORAL Discontinued —
EQ 100MG BASE TABLET ORAL Discontinued —
SUMATRIPTAN SUCCINATERS
EUGIA PHARMAANDA 2027582013
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Rx AP
SUMATRIPTAN SUCCINATE
ZHEJIANGANDA 20026320123 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Rx AB
EQ 50MG BASE TABLET ORAL Rx AB
EQ 100MG BASE TABLET ORAL Rx AB
SUMATRIPTAN SUCCINATE
SUN PHARMANDA 0903582011
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Rx AB
SUMATRIPTAN SUCCINATE
ZYDUSANDA 0903102010
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Discontinued —
SUMATRIPTAN SUCCINATE
ONESOURCE SPECIALTYANDA 0906412010
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Discontinued —

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Discontinued	—
EQ 50MG BASE	TABLET	ORAL	Discontinued	—
EQ 100MG BASE	TABLET	ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Rx	AB
EQ 50MG BASE	TABLET	ORAL	Rx	AB
EQ 100MG BASE	TABLET	ORAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AB

SUMATRIPTAN SUCCINATE

ONESOURCE SPECIALTYANDA 09031420102 strengths

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Discontinued	—
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AB

SUMATRIPTAN SUCCINATE
MYLANANDA 07716320093 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Discontinued —
EQ 50MG BASE TABLET ORAL Discontinued —
EQ 100MG BASE TABLET ORAL Discontinued —
SUMATRIPTAN SUCCINATE
PH HEALTHANDA 0773322009
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Discontinued —

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Discontinued	—
EQ 50MG BASE	TABLET	ORAL	Discontinued	—
EQ 100MG BASE	TABLET	ORAL	Discontinued	—

SUMATRIPTAN SUCCINATE

FRESENIUS KABI USAANDA 07924020092 strengths

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Discontinued	—
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Discontinued	—

SUMATRIPTAN SUCCINATE
AUROBINDO PHARMAANDA 07832720093 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Rx AB
EQ 50MG BASE TABLET ORAL Rx AB
EQ 100MG BASE TABLET ORAL Rx AB
SUMATRIPTAN SUCCINATE
DR REDDYS LABS INCANDA 07684720093 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Rx AB
EQ 50MG BASE TABLET ORAL Rx AB
EQ 100MG BASE TABLET ORAL Rx AB
SUMATRIPTAN SUCCINATE
FOSUN PHARMAANDA 07697620093 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Discontinued —
EQ 50MG BASE TABLET ORAL Discontinued —
EQ 100MG BASE TABLET ORAL Discontinued —
SUMATRIPTAN SUCCINATE
MYLANANDA 07774420093 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Rx AB
EQ 50MG BASE TABLET ORAL Rx AB
EQ 100MG BASE TABLET ORAL Rx AB
SUMATRIPTAN SUCCINATE
ORBION PHARMSANDA 07828420093 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Rx AB
EQ 50MG BASE TABLET ORAL Rx AB
EQ 100MG BASE TABLET ORAL Rx AB
SUMATRIPTAN SUCCINATE
ROXANEANDA 07824120093 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Discontinued —
EQ 50MG BASE TABLET ORAL Discontinued —
EQ 100MG BASE TABLET ORAL Discontinued —
SUMATRIPTAN SUCCINATE
SUN PHARM INDSANDA 07829520093 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Discontinued —
EQ 50MG BASE TABLET ORAL Discontinued —
EQ 100MG BASE TABLET ORAL Discontinued —
SUMATRIPTAN SUCCINATE
SUN PHARM INDS LTDANDA 07655420092 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Discontinued —
EQ 50MG BASE TABLET ORAL Discontinued —
SUMATRIPTAN SUCCINATE
WATSON LABSANDA 07693320093 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Rx AB
EQ 50MG BASE TABLET ORAL Rx AB
EQ 100MG BASE TABLET ORAL Rx AB
SUMATRIPTAN SUCCINATE
PH HEALTHANDA 0778712009
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Discontinued —
SUMATRIPTAN SUCCINATE
FRESENIUS KABI USAANDA 0792422009
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Rx AP
SUMATRIPTAN SUCCINATE
SUN PHARM INDS LTDANDA 0765722009
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 100MG BASE TABLET ORAL Discontinued —
SUMATRIPTAN SUCCINATE
TEVAANDA 07684020093 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 25MG BASE TABLET ORAL Discontinued —
EQ 50MG BASE TABLET ORAL Discontinued —
EQ 100MG BASE TABLET ORAL Discontinued —
SUMATRIPTAN SUCCINATE
HIKMAANDA 0791232009
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Rx AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Rx	AB
EQ 50MG BASE	TABLET	ORAL	Rx	AB
EQ 100MG BASE	TABLET	ORAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Rx	AB
EQ 50MG BASE	TABLET	ORAL	Rx	AB
EQ 100MG BASE	TABLET	ORAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Discontinued	—
EQ 50MG BASE	TABLET	ORAL	Discontinued	—
EQ 100MG BASE	TABLET	ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Rx	AB
EQ 50MG BASE	TABLET	ORAL	Rx	AB
EQ 100MG BASE	TABLET	ORAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Rx	AB
EQ 50MG BASE	TABLET	ORAL	Rx	AB
EQ 100MG BASE	TABLET	ORAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Discontinued	—
EQ 50MG BASE	TABLET	ORAL	Discontinued	—
EQ 100MG BASE	TABLET	ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Discontinued	—
EQ 50MG BASE	TABLET	ORAL	Discontinued	—
EQ 100MG BASE	TABLET	ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Discontinued	—
EQ 50MG BASE	TABLET	ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Rx	AB
EQ 50MG BASE	TABLET	ORAL	Rx	AB
EQ 100MG BASE	TABLET	ORAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 100MG BASE	TABLET	ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 25MG BASE	TABLET	ORAL	Discontinued	—
EQ 50MG BASE	TABLET	ORAL	Discontinued	—
EQ 100MG BASE	TABLET	ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AP

SUMATRIPTAN SUCCINATE

SANDOZANDA 07806720092 strengths

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Discontinued	—
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Discontinued	—

SUMATRIPTAN SUCCINATE

TEVA PARENTERALANDA 07831820092 strengths

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Discontinued	—
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Discontinued	—

SUMATRIPTAN SUCCINATE
TEVA PHARMS USAANDA 0779072009
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Discontinued —
SUMATRIPTAN SUCCINATE
WOCKHARDT BIO AGANDA 0785932009
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE SUBCUTANEOUS Rx AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	INJECTABLE	SUBCUTANEOUS	Rx	AP

Patent & exclusivity timeline

Protection horizon

Patent expiryExclusivity endToday

Listed patents

Orange Book patent file

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
Patent	Expires	In	Type
11571531	Feb 23, 2026	6 mo ago	U-1809
7901385	Jul 31, 2026	23 d ago	Product
7776007	Nov 22, 2026	in 3 mo	Product
10124132	Mar 06, 2027	in 7 mo	ProductU-2010
7973058	Apr 12, 2027	in 8 mo	U-1328
8155737	Apr 12, 2027	in 8 mo	U-1328
8470853	Apr 12, 2027	in 8 mo	U-1328
9427578	Apr 12, 2027	in 8 mo	ProductU-1328
8597272	Apr 12, 2027	in 8 mo	Product
7811254	Aug 26, 2027	in 1 yr	ProductU-1083
9272137	Sep 07, 2027	in 1 yr 1 mo	Product
10398859	Dec 19, 2027	in 1 yr 4 mo	Product
8875704	Apr 07, 2028	in 1 yr 8 mo	ProductU-1809
10722667	Dec 30, 2028	in 2 yr 5 mo	Product
8366600	Apr 21, 2029	in 2 yr 8 mo	U-1327
10076615	Jul 30, 2029	in 3 yr	U-2011
8550073	Oct 22, 2029	in 3 yr 3 mo	Product
8899229	Aug 18, 2030	in 4 yr 1 mo	Product
9649456	Oct 21, 2030	in 4 yr 3 mo	ProductU-1719
8983594	Nov 19, 2030	in 4 yr 4 mo	ProductU-1328
8978647	Dec 06, 2030	in 4 yr 4 mo	Product
9327114	Oct 08, 2032	in 6 yr 3 mo	ProductU-1328
10478574	Nov 04, 2033	in 7 yr 4 mo	U-2404
10076614	Oct 20, 2034	in 8 yr 3 mo	Product
10537554	Jan 29, 2036	in 9 yr 7 mo	U-72
11364224	Jan 29, 2036	in 9 yr 7 mo	U-72
12097183	Jan 29, 2036	in 9 yr 7 mo	Product

Approval history

FDA approval span

First approval

Dec 28, 1992

34 yr 2 mo ago

Most recent approval

Jan 30, 2026

7 mo ago

Approvals span 1992–2026 across 45 FDA applications.

Brand (NDA) 716%

Generic (ANDA) 3884%

Sumatriptan succinate: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo